<DOC>
	<DOCNO>NCT02079922</DOCNO>
	<brief_summary>PF-06678552 new compound propose treatment hypercholesteremia . The primary purpose study evaluate safety tolerability , pharmacokinetics , pharmacodynamics multiple oral dos PF-06678552 healthy subject .</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-06678552 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential . Body Mass Index ( BMI ) 18 30.5 kg/m2 ; total body weight &gt; 50 kg Low density lipoprotein cholesterol 115 mg/dL 190 mg/dL Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Multiple Ascending Dose</keyword>
	<keyword>healthy subject</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>